GGrantIndex
← Leaderboards

Susan E Waltz

Cincinnati Va Medical Center Research

Google Scholar ↗PubMed ↗ORCID ↗
$10,100,074
Attributed
$13,833,893
Total exposure
11
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,833,893 · 9
VA$0 · 2

By mechanism

R01$7,361,072 · 5
T32$6,235,821 · 3
R21$237,000 · 1
I01$0 · 2

Top collaborators

Others in their field

Top investigators on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsPathway InteractionsSignal TransductionReceptor Protein-Tyrosine KinasesNeoplasm MetastasisGrowthTumorTumor GrowthSignal PathwayCellsCessation Of LifeLaboratoriesReceptorOverexpressionTumor ProgressionProteinsMediatingIn VivoBaseProtein Tyrosine KinaseRegulationNeoplastic CellClinically RelevantProduction

Grant awards (60)

Training Program in Basic and Translational Oncology$383,491
T32 · FY2025 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2025 · VA · contact PI
Defining genetic and metabolic requirements of aggressive breast cancer$452,218
R01 · FY2024 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2024 · VA · contact PI
Defining genetic and metabolic requirements of aggressive breast cancer$466,499
R01 · FY2023 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2023 · VA · contact PI
Defining genetic and metabolic requirements of aggressive breast cancer$466,496
R01 · FY2022 · CA · contact PI
Pathways to Cancer Therapeutics$436,475
T32 · FY2022 · CA · contact PI
Pathways to Cancer Therapeutics$527,542
T32 · FY2021 · CA · contact PI
Defining genetic and metabolic requirements of aggressive breast cancer$476,019
R01 · FY2021 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2021 · VA · contact PI
Pathways to Cancer Therapeutics$550,112
T32 · FY2020 · CA · contact PI
Defining genetic and metabolic requirements of aggressive breast cancer$506,269
R01 · FY2020 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2020 · VA · contact PI
Pathways to Cancer Therapeutics$381,135
T32 · FY2019 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2019 · VA · contact PI
Pathways to Cancer Therapeutics$459,588
T32 · FY2018 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2018 · VA · contact PI
Training Program in Cancer Therapeutics$11,331
T32 · FY2017 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2017 · VA · contact PI
Training Program in Cancer Therapeutics$471,850
T32 · FY2016 · CA · contact PI
Early exposure to phthalate & obesity: the role of PCNA tyrosine phosphorylation$237,000
R21 · FY2016 · ES · contact PI
Training Program in Cancer Therapeutics$46,970
T32 · FY2016 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2016 · VA · contact PI
Training Program in Cancer Therapeutics$464,294
T32 · FY2015 · CA · contact PI
Training Program in Cancer Therapeutics$46,154
T32 · FY2015 · CA · contact PI
Training Program in Cancer Therapeutics$387,088
T32 · FY2014 · CA · contact PI
Training Program in Cancer Therapeutics$45,674
T32 · FY2014 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2014 · VA · contact PI
Training Program in Cancer Therapeutics$327,677
T32 · FY2013 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2013 · VA · contact PI
Training Program in Cancer Therapeutics$415,265
T32 · FY2012 · CA · contact PI
The Ron Receptor/Chemokine Axis in Prostate Cancer$313,989
R01 · FY2012 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2012 · VA · contact PI
The Ron Receptor/Chemokine Axis in Prostate Cancer$0
I01 · FY2012 · VA · contact PI
The Ron Receptor/Chemokine Axis in Prostate Cancer$313,989
R01 · FY2011 · CA · contact PI
Ron Receptor Tyrosine Kinase Signaling in Breast Cancer$0
I01 · FY2011 · VA · contact PI
Training Program in Cancer Therapeutics$395,220
T32 · FY2010 · CA · contact PI
The Ron Receptor/Chemokine Axis in Prostate Cancer$1
R01 · FY2010 · CA · contact PI
The Ron Receptor/Chemokine Axis in Prostate Cancer$323,700
R01 · FY2009 · CA · contact PI
Training Program in Cancer Therapeutics$316,191
T32 · FY2009 · CA · contact PI
Hepatocyte Growth Factor-like Protein Receptor$288,835
R01 · FY2009 · DK · contact PI
The Ron Receptor/Chemokine Axis in Prostate Cancer$0
I01 · FY2009 · VA · contact PI
Training Program in Cancer Therapeutics$346,294
T32 · FY2008 · CA · contact PI
The Ron Receptor/Chemokine Axis in Prostate Cancer$323,700
R01 · FY2008 · CA · contact PI
Hepatocyte Growth Factor-like Protein Receptor$288,835
R01 · FY2008 · DK · contact PI
The Ron Receptor in Mammary Gland Biology$268,531
R01 · FY2008 · CA · contact PI
Hepatocyte Growth Factor-like Protein Receptor$294,731
R01 · FY2007 · DK · contact PI
The Ron Receptor in Mammary Gland Biology$268,531
R01 · FY2007 · CA · contact PI
Research in Alimentary Tract Surgery$223,470
T32 · FY2007 · DK · contact PI
Hepatocyte Growth Factor-like Protein Receptor$303,532
R01 · FY2006 · DK · contact PI
The Ron Receptor in Mammary Gland Biology$276,552
R01 · FY2006 · CA · contact PI
Hepatocyte Growth Factor-like Protein Receptor$310,838
R01 · FY2005 · DK
The Ron Receptor in Mammary Gland Biology$283,208
R01 · FY2005 · CA
The Ron Receptor in Mammary Gland Biology$283,208
R01 · FY2004 · CA
The Ron Receptor in Mammary Gland Biology$76,036
R01 · FY2004 · CA
HEPATOCYTE GROWTH FACTOR LIKE PROTEIN RECEPTOR$211,153
R01 · FY2003 · HD
HEPATOCYTE GROWTH FACTOR LIKE PROTEIN RECEPTOR$193,652
R01 · FY2002 · HD
HEPATOCYTE GROWTH FACTOR LIKE PROTEIN RECEPTOR$188,014
R01 · FY2001 · HD
HEPATOCYTE GROWTH FACTOR LIKE PROTEIN RECEPTOR$182,536
R01 · FY2000 · HD